Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol

Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol

Abstract Background Kawasaki disease (KD) is an acute self-limiting inflammatory vasculitis affecting predominantly medium-sized arteries, particularly the coronary arteries. A number of recent studies conducted in different European countries have demonstrated alarmingly high coronary complications...

Full description

Bibliographic Details
Main Authors: Despina Eleftheriou, Yolanda Collaco Moraes, Cara Purvis, Molly Pursell, Marta Merida Morillas, Robin Kahn, Maria Mossberg, Filip Kucera, Robert Tulloh, Joseph F. Standing, Veronica Swallow, Rachael McCormack, Jethro Herberg, Michael Levin, Mandy Wan, Nigel Klein, Roisin Connon, Ann Sarah Walker, Paul Brogan
Format: Article
Language:English
Published: BMC 2023-01-01
Series:Trials
Subjects:
Kawasaki disease
Corticosteroids
Coronary artery aneurysms
Online Access:https://doi.org/10.1186/s13063-022-07051-9

Internet

https://doi.org/10.1186/s13063-022-07051-9

Similar Items